The Effect of Povidone‐Iodine Nasal Spray on Nasopharyngeal SARS‐CoV‐2 Viral Load: A Randomized Control Trial
| Autor: | Katie M Phillips, Vidya K. Rao, Neelaysh Vukkadala, Zara M. Patel, Z Jason Qian, Jayakar V. Nayak, Ivan T. Lee, Peter H. Hwang, George H. Domb, Benjamin A. Pinsky, Kenji O. Mfuh, David Zarabanda, Matthew Hatter |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Nasal cavity
medicine.medical_treatment Nostril macromolecular substances nasal spray Placebo cycle threshold law.invention coronavirus disease 2019 Randomized controlled trial law Original Reports medicine Severe acute respiratory syndrome coronavirus 2 Humans Adverse effect Povidone-Iodine Saline povidone‐iodine SARS-CoV-2 business.industry technology industry and agriculture clinical trial Nasal Sprays Viral Load nasopharyngeal swab COVID-19 Drug Treatment medicine.anatomical_structure Otorhinolaryngology Nasal spray Anesthesia Saline Solution business Viral load |
| Zdroj: | The Laryngoscope |
| ISSN: | 1531-4995 0023-852X |
| DOI: | 10.1002/lary.29935 |
| Popis: | Objectives To determine the effect of povidone-iodine (PVP-I) nasal sprays on nasopharyngeal (NP) viral load as assessed by cycle threshold on quantitative polymerase chain reaction (qPCR) of SARS-CoV-2 in outpatients. Study design Three arm, triple blinded, randomized, placebo-controlled clinical trial. Methods Participants were randomized within 5 days of testing positive for COVID-19 to receive nasal sprays containing either placebo (0.9% saline), 0.5% PVP-I, or 2.0% PVP-I. NP swabs for qPCR analysis were taken at baseline, 1-hour post-PVP-I spray (2 sprays/nostril), and 3 days post-PVP-I spray (20 sprays/nostril). Symptom and adverse event questionnaires were completed at baseline, day 3, and day 5. University of Pennsylvania Smell Identification Tests (UPSIT) were completed at baseline and day 30. Results Mean cycle threshold (Ct) values increased over time in all groups, indicating declining viral loads, with no statistically significant difference noted in the rate of change between placebo and PVP-I groups. 2.0% PVP-I group showed statistically significant improvement in all symptom categories, however also reported a high rate of nasal burning. Olfaction via UPSIT showed improvement by at least one category in all groups. There were no hospitalizations or mortalities within 30 days of study enrollment. Conclusion Saline and low concentration PVP-I nasal sprays are well tolerated. Similar reductions in SARS-CoV-2 nasopharyngeal viral load were seen over time in all groups. All treatment groups showed improvement in olfaction over 30 days. These data suggest that dilute versions of PVP-I nasal spray are safe for topical use in the nasal cavity, but that PVP-I does not demonstrate virucidal activity in COVID-19 positive outpatients. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text